|
Anti HLA Antibodies in Hemato-oncologic Patients with and without Platelet Refractoriness
|
M. Shaiegan    , M. Mostakhdemin , M. Alaei , E. Ebrahinzadeh , A. Chegini , S. Mohammadi |
|
|
| Keywords: Platelets, Histocompatibility Antigens, HLA |
|
|
Full-Text [PDF 485 kb]
(594 Downloads)
| Abstract (HTML) (1251 Views)
|
Type of Study: Research |
Subject:
Blood transfusion medicine
Published: 2021/07/1
|
|
|
|
|
|
|
Full-Text: (1033 Views) |
References:
- Brouk H, Bertrand G, Zitouni S, Djenouni A, Martageix C, Griffi F, et al. HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness. Transfus Apher Sci 2015; 52(3): 295-9.
- Ferreira AA, Zulli R, Soares S, Castro Vd, Moraes-Souza H. Identification of platelet refractoriness in oncohematologic patients. Clinics (Sao Paulo) 2011; 66(1): 35-40.
- Rosenfeld CS, Bodensteiner DC. Detection of Platelet Alloantibodies by Flow Cytometry. Am J Clin Pathol 1986; 85: 207-12.
- Fabris F, Soini B, Sartori R, Randi ML, Luzzatto G, Girolami A. Clinical and laboratory factors that affect the post-transfusion platelet increment. Transfus Sci 2000; 23(1): 63-8.
- Heal JM, Blumberg N. Optimizing platelet transfusion therapy. Blood Rev 2004; 18: 149-65.
- Sarkar RS, Philip J, Jain N. Detection and Identification of Platelet-Associated Alloantibodies by a Solid-Phase Modified Antigen Capture Elisa (MACE) technique and its correlation to platelet refractoriness in multi platelet concentrate transfused patients. Indian J Hematol Blood Transfus 2015; 31: 77-84.
- Apelseth TO, Hervig T, Bruserud O. Current practice and future directions for optimization of platelet transfusions in patients with severe therapy-induced cytopenia. Blood Rev 2011; 25(3): 113-22.
- Mostakhdemin M, Shaiegan M , Kasraeian L, Khosravi A, Yari F, Shayegan Sh. Antibody against Human Leukocyte Antigens in female blood donors with and without previous abortion. Iran J Obstet Gynecol Infert 2019; 21(12): 85-93. [Article in Farsi]
- Mostakhdemin Hosseini M, Samiee S, Shaiegan M, Mohammadi S, Jalaiekhoo H, Tabatabiepanah P, et al . Evaluation of platelet antigens and antibodies in patients with platelet refractoriness. Sci J Iran Blood Transfus Organ 2019; 16(2): 91-102. [Article in Farsi]
- Hod E, Schwartz J. Platelet transfusion refractoriness.
Br J Haematol 2008; 142(3): 348-60.
- İnal A, Özçelik Ü, Ogan Uyanık E, Külah E, Demirağ A. Analysis of Panel Reactive Antibodies in Renal Transplant Recipients Detected by Luminex: A Single-Center Experience. Exp Clin Transplant 2016; 14(4): 401-4.
- Peña JRA, Saidman SL, Girouard TC, Meister E, Dzik WH, Makar RS. Anti-HLA alloantibodies in surgical patients refractory to platelet transfusion. Am J Hematol 2014; 89(9): E133-7.
- Rijkers M , Schmidt D, Lu N, Kramer CSM, Heidt S, Mulder A, et al. Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets. Haematologica 2019; 104(2): 403-16.
- Shaiegan M, Amiri F, Derakhti Gonbad MH, Aghaeipour M, Maghsudlu M, Tabatabaian A, et al. Flowcytometric evaluation of antibodies against histocompatibility antigens and platelet-specific antigens in patients with hematological disorders following the transfusion of platelets concentrates. Sci J Iran Blood Transfus Organ 2005, 1(2): 27-36. [Article in Farsi]
- Wang J, Xia W, Deng J, Xu X, Shao Y, Ding H, et al. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness. Transfus Med 2018, 28: 40-6.
- Imoto S, Kawamura K, Tokumine Y, Araki N, Akita S, Nishimura C, et al. Acute non-hemolytic transfusion reactions and HLA class I antibody: advantages of solid phase assay compared with conventional complement-dependent assay. Transfus Med 2010; 20: 95-103.
- Kumawat V, Sharma RR, Malhotra P, Marwaha N. Prevalence of risk factors for platelet transfusion refractoriness in multitransfused hemato-oncological patients at tertiary care center in North India. Asian J Transfus Sci 2015; 9(1): 61-4.
|
Sci J Iran Blood Transfus Organ 2021;18(2): 79-86
|
Anti HLA Antibodies in Hemato-oncologic Patients with
and without Platelet Refractoriness
Shaiegan M.1, Mostakhdemin Hosseini M.1, Alaei M.1, Ebrahimzadeh E.1,
Chegini A.1, Mohammadi S.2
1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
2Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Shariati Hospital, Tehran, Iran
Abstract
Background and Objectives
Various antibodies such as antibodies against RBC antigens, anti-HLA, and anti-platelet antibodies are developed after repeated blood transfusions and may lead to transfusion reactions such as platelet refractoriness in recipients. In this study, anti-HLA antibodies were evaluated in hemato-oncological patients, with and without simultaneous platelet refractoriness .
Materials and Methods
In this descriptive study, performed from 2017 to 2019, presence of anti-HLA antibodies in patients with hemato-oncological disorders, referred to the HSCT Research Center, Shariati Hospital, Tehran, was assessed using Panel Reactive Antibody (PRA) test based on complement lymphocytotoxicity. Data analysis was performed by SPSS (version 16) and chi-square tests.
Results
Of 79 studied patients with hemato-oncological disorders including 34 females (43%) and 45 males (57%) with the age range of 2 to 83 years, 49 were platelet refractory and 30 were not. Anti-HLA antibodies were present in 39 (49.4%) patients and 40 (50.6%) were negative for them. The frequency of panel reactive antibody positive cases was significantly different between patients with platelet refractoriness (62.8%) and those without it (30%) (P = 0.007).
Conclusions
The role of anti-HLA antibodies in platelet refractoriness is well established. Our study also showed a significant difference in this regard among two groups of hemato-oncological patients with and without platelet refractoriness. The presence of these antibodies does not always mean platelet refractoriness, and antibodies without the ability to activate complement can also cause this complication.
Key words: Platelets, Histocompatibility Antigens, HLA
Received: 13 Feb 2021
Accepted:27 Feb 2021
Correspondence: Alaei M., MD. Specialist in Pathology. Assistant Professor of Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine.
P.O.Box: 14665-1157, Tehran, Iran. Tel: (+9821) 82052234; Fax: (+9821) 88628741
E-mail: alaeimastaneh@hotmail.com |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Shaiegan M, Mostakhdemin M, Alaei M, Ebrahinzadeh E, Chegini A, Mohammadi S. Anti HLA Antibodies in Hemato-oncologic Patients with and without Platelet Refractoriness. Sci J Iran Blood Transfus Organ 2021; 18 (2) :79-86 URL: http://bloodjournal.ir/article-1-1396-en.html
|
.jpg)
.png)
